Established in 1997, Zhejiang Starry Pharmaceutical Co., Ltd. is a high-tech enterprise specialized in research and development, production and sales of X-CT nonionic iodine contrast agent series and quinolone series bulk drugs and intermediates. It is currently the production base of diagnostic bulk drugs in China. The company was listed on the Shanghai Stock Exchange on March 9, 2016 (Stock Code: 603520).
Over the past 20 years, the company has maintained a good and stable development momentum and has become the leading enterprise of X-CT nonionic contrast agent bulk drugs in China. The products that have the industrialization capability include iohexol bulk drug, iopamidol bulk drug, iodophor bulk drug, iopromide bulk drug, iodixanol bulk drug, etc. Among them, the production capacity and output of iohexol bulk drug rank first in China. With stable quality, the company's products have been certified by many developed countries. At present, there are 4 manufacturers of iohexol bulk drug worldwide that have obtained EU CEP certificate, among whom Starry is the only one in China. In addition, Starry is among the 4 manufacturers of iohexol bulk drug worldwide that have obtained Japan’s access certificate.
In terms of quinolone series bulk drug, the company is at the domestic leading level in the separation and synthesis of impurities in levofloxacin series products, ranking fourth in the country in production scale, and is one of the largest levofloxacin series manufacturers in China.
Attaching great importance to independent research and development capabilities, the company has long focused on the sustainable development strategy of X-ray contrast agents and achieved fruitful results. The company is Zhejiang Enterprise Technology Center and Zhejiang Nonionic Contrast Agent High-tech Research Center. The "nonionic X-CT contrast agent bulk drug - Iohexol" project and the "industrialization of pazufloxacin" (a key intermediate of the fourth generation quinolone antibacterial drug) project undertaken by the company have both obtained the "national torch plan project certificate" issued by the Torch High-tech Industry Development Center of the Ministry of Science and Technology of the People's Republic of China. Iohexol and pazufloxacin were also rated as "high-tech products of Zhejiang province" by Zhejiang Science and Technology Department. "Development and industrialization of synthetic process for high-purity nonionic X-CT contrast agent - iohexol" project won the Second Prize of Zhejiang Provincial Science and Technology Progress Award and the First Prize of Taizhou Municipal Science and Technology Progress Award issued by Zhejiang Provincial People's Government and Taizhou Municipal People's Government respectively.
Deeming "gathering life energy and caring for human health" as its business philosophy and "replacing imports with specialized products and filling domestic gaps" as its development policy, the company has continuously enriched X-ray contrast agent series products and strived to maximize the scale of existing core products of X-ray contrast agent bulk drugs. At the same time, it is committed to developing new drugs with independent intellectual property rights and accelerating its development into the field of preparations. The company will strive to become a well-known pharmaceutical enterprise in China and even in the world while building Starry into an outstanding pharmaceutical brand.